April 18, 2024 06:30 AM EDT
R&D

Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

Max Gelman

Senior Editor

Amber Tong

As it waits for its ac­qui­si­tion by Ab­b­Vie to fi­nal­ize, Cerev­el re­port­ed a Phase 3 win for one of its pro­grams in Parkin­son’s dis­ease. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times